ETF Holdings Breakdown of CGON

CGON institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-09-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	25,131	USD 943,418
2025-09-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	9,858	USD 370,069
2025-09-26	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	74,545	USD 2,798,419
2025-09-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	43,238	USD 1,623,155
2025-09-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	43,238	USD 1,623,155
Total =		196,010	USD 7,358,216

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with CGON

CG Oncology (NASDAQ:CGON) Stock Price Expected to Rise, Morgan Stanley Analyst Says

CG Oncology (NASDAQ:CGON – Get Free Report) had its target price lifted by Morgan Stanley from $56.00 to $79.00 in a report issued on Wednesday, MarketBeat reports. The firm presently has an “overweight” rating on the stock. Morgan Stanley’s price target indicates a potential upside of 103.50% from the stock’s current price. CGON has been […] - 2025-09-19 02:36:47

CG Oncology (NASDAQ:CGON) Shares Gap Up on Insider Buying Activity

CG Oncology, Inc. (NASDAQ:CGON – Get Free Report)’s share price gapped up prior to trading on Monday after an insider bought additional shares in the company. The stock had previously closed at $33.34, but opened at $35.10. CG Oncology shares last traded at $34.33, with a volume of 114,584 shares. Specifically, Director Brian Guan-Chyun Liu […] - 2025-09-17 02:12:49

CG Oncology (NASDAQ:CGON) Coverage Initiated at Jones Trading

Stock analysts at Jones Trading assumed coverage on shares of CG Oncology (NASDAQ:CGON – Get Free Report) in a research note issued to investors on Monday,Benzinga reports. The brokerage set a “buy” rating and a $50.00 price target on the stock. Jones Trading’s price objective points to a potential upside of 49.39% from the stock’s […] - 2025-09-10 02:40:50

Brokerages Set CG Oncology, Inc. (NASDAQ:CGON) Price Target at $54.30

Shares of CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy […] - 2025-09-09 02:29:01

CG Oncology (NASDAQ:CGON) Upgraded by Zacks Research to “Hold” Rating

Zacks Research upgraded shares of CG Oncology (NASDAQ:CGON – Free Report) from a strong sell rating to a hold rating in a research note published on Monday,Zacks.com reports. CGON has been the topic of a number of other research reports. Piper Sandler began coverage on CG Oncology in a report on Monday, August 18th. They […] - 2025-09-04 03:02:54

Analysts Set CG Oncology, Inc. (NASDAQ:CGON) Price Target at $55.30

Shares of CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) have earned an average recommendation of “Buy” from the twelve research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating […] - 2025-08-15 02:24:52

CG Oncology, Inc. (NASDAQ:CGON) Receives $55.30 Average Target Price from Brokerages

CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) has been given an average recommendation of “Buy” by the twelve ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating […] - 2025-07-21 02:30:49

Brokerages Set CG Oncology, Inc. (NASDAQ:CGON) PT at $58.67

Shares of CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) have earned an average recommendation of “Buy” from the eleven research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, nine have given a buy recommendation and one has assigned a strong buy recommendation […] - 2025-06-26 02:23:03

CG Oncology (NASDAQ:CGON) Price Target Raised to $56.00

CG Oncology (NASDAQ:CGON – Get Free Report) had its target price hoisted by investment analysts at Morgan Stanley from $52.00 to $56.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Morgan Stanley’s target price would indicate a potential upside of 113.09% from the stock’s current price. […] - 2025-06-19 02:56:48

CG Oncology (NASDAQ:CGON) Trading Up 4.7% After Analyst Upgrade

CG Oncology, Inc. (NASDAQ:CGON – Get Free Report)’s stock price traded up 4.7% during trading on Tuesday after Morgan Stanley raised their price target on the stock from $52.00 to $56.00. Morgan Stanley currently has an overweight rating on the stock. CG Oncology traded as high as $26.31 and last traded at $26.65. 213,112 shares […] - 2025-06-19 02:13:09

CG Oncology, Inc. (NASDAQ:CGON) Position Decreased by Nuveen Asset Management LLC

Nuveen Asset Management LLC decreased its holdings in shares of CG Oncology, Inc. (NASDAQ:CGON – Free Report) by 27.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 111,716 shares of the company’s stock after selling 41,918 shares during the period. […] - 2025-06-02 04:58:49

ProShare Advisors LLC Acquires 7,599 Shares of CG Oncology, Inc. (NASDAQ:CGON)

ProShare Advisors LLC boosted its holdings in CG Oncology, Inc. (NASDAQ:CGON – Free Report) by 84.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 16,561 shares of the company’s stock after acquiring an additional 7,599 shares during the period. ProShare Advisors […] - 2025-05-27 06:37:07

Morgan Stanley Has Lowered Expectations for CG Oncology (NASDAQ:CGON) Stock Price

CG Oncology (NASDAQ:CGON – Get Free Report) had its price objective dropped by investment analysts at Morgan Stanley from $55.00 to $52.00 in a report released on Monday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley’s price target indicates a potential upside of 95.78% from the stock’s current price. A […] - 2025-05-21 02:56:59

CG Oncology (NASDAQ:CGON) Shares Gap Down After Earnings Miss

CG Oncology, Inc. (NASDAQ:CGON – Get Free Report)’s share price gapped down prior to trading on Tuesday following a weaker than expected earnings announcement. The stock had previously closed at $25.16, but opened at $24.21. CG Oncology shares last traded at $24.95, with a volume of 42,738 shares. The company reported ($0.45) earnings per share […] - 2025-05-15 02:18:49

CG Oncology, Inc. (NASDAQ:CGON) Receives $57.70 Consensus Price Target from Brokerages

Shares of CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) have earned a consensus recommendation of “Buy” from the twelve analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, ten have issued a buy recommendation and one has issued a strong buy recommendation on the […] - 2025-05-07 02:19:09

CG Oncology, Inc. (NASDAQ:CGON) Shares Acquired by Wells Fargo & Company MN

Wells Fargo & Company MN grew its stake in CG Oncology, Inc. (NASDAQ:CGON – Free Report) by 45.3% during the fourth quarter, HoldingsChannel reports. The firm owned 28,234 shares of the company’s stock after purchasing an additional 8,803 shares during the quarter. Wells Fargo & Company MN’s holdings in CG Oncology were worth $810,000 as […] - 2025-05-01 05:08:57

Legal & General Group Plc Acquires 2,793 Shares of CG Oncology, Inc. (NASDAQ:CGON)

Legal & General Group Plc raised its position in CG Oncology, Inc. (NASDAQ:CGON – Free Report) by 10.6% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 29,262 shares of the company’s stock after acquiring an additional 2,793 shares during the period. Legal & General Group Plc’s holdings in CG Oncology were worth $839,000 […] - 2025-04-28 05:02:55

Vanguard Group Inc. Boosts Stock Position in CG Oncology, Inc. (NASDAQ:CGON)

Vanguard Group Inc. lifted its stake in CG Oncology, Inc. (NASDAQ:CGON – Free Report) by 15.3% in the fourth quarter, Holdings Channel.com reports. The fund owned 5,861,082 shares of the company’s stock after purchasing an additional 779,730 shares during the period. Vanguard Group Inc. owned approximately 0.08% of CG Oncology worth $168,096,000 as of its […] - 2025-04-07 04:41:00

HC Wainwright Reaffirms “Buy” Rating for CG Oncology (NASDAQ:CGON)

CG Oncology (NASDAQ:CGON – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $75.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 240.14% from the company’s […] - 2025-04-02 02:46:56

Corebridge Financial Inc. Has $2.67 Million Holdings in CG Oncology, Inc. (NASDAQ:CGON)

Corebridge Financial Inc. decreased its stake in shares of CG Oncology, Inc. (NASDAQ:CGON – Free Report) by 31.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 93,189 shares of the company’s stock after selling 42,440 shares during the quarter. Corebridge Financial […] - 2025-04-01 05:30:53

HC Wainwright Reaffirms “Buy” Rating for CG Oncology (NASDAQ:CGON)

HC Wainwright restated their buy rating on shares of CG Oncology (NASDAQ:CGON – Free Report) in a research report released on Tuesday,Benzinga reports. They currently have a $75.00 price objective on the stock. Other equities research analysts also recently issued research reports about the stock. Royal Bank of Canada restated an “outperform” rating and issued […] - 2025-03-26 04:52:43

Intech Investment Management LLC Acquires Shares of 16,787 CG Oncology, Inc. (NASDAQ:CGON)

Intech Investment Management LLC bought a new position in shares of CG Oncology, Inc. (NASDAQ:CGON – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 16,787 shares of the company’s stock, valued at approximately $481,000. Several other hedge funds […] - 2025-03-25 06:31:03

Bank of New York Mellon Corp Cuts Stock Position in CG Oncology, Inc. (NASDAQ:CGON)

Bank of New York Mellon Corp lowered its position in CG Oncology, Inc. (NASDAQ:CGON – Free Report) by 6.5% during the fourth quarter, Holdings Channel reports. The institutional investor owned 135,567 shares of the company’s stock after selling 9,359 shares during the quarter. Bank of New York Mellon Corp’s holdings in CG Oncology were worth […] - 2025-03-19 05:10:48

Rhumbline Advisers Boosts Stock Position in CG Oncology, Inc. (NASDAQ:CGON)

Rhumbline Advisers increased its position in shares of CG Oncology, Inc. (NASDAQ:CGON – Free Report) by 2.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 69,016 shares of the company’s stock after acquiring an additional 1,458 shares during the quarter. Rhumbline Advisers’ […] - 2025-03-04 06:10:52

13,300 Shares in CG Oncology, Inc. (NASDAQ:CGON) Bought by Handelsbanken Fonder AB

Handelsbanken Fonder AB purchased a new position in shares of CG Oncology, Inc. (NASDAQ:CGON – Free Report) in the fourth quarter, HoldingsChannel.com reports. The firm purchased 13,300 shares of the company’s stock, valued at approximately $381,000. A number of other large investors have also recently bought and sold shares of CGON. State Street Corp boosted […] - 2025-03-03 06:59:06

Analysts Set CG Oncology, Inc. (NASDAQ:CGON) Target Price at $63.88

Shares of CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) have earned an average recommendation of “Buy” from the nine research firms that are covering the firm, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month […] - 2025-02-21 04:33:00

Critical Analysis: CG Oncology (NASDAQ:CGON) & OKYO Pharma (NASDAQ:OKYO)

OKYO Pharma (NASDAQ:OKYO – Get Free Report) and CG Oncology (NASDAQ:CGON – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings. Analyst Recommendations This is a breakdown of current […] - 2025-02-19 05:06:50

Back to Listing

Disclaimer